By Dr. Pan Meng Pemphigus is a group of organ-specific autoimmune disorders, including pemphigus vulgaris (PV), pemphigus foliaceus (PF) and paraneoplastic pemphigus (PNP). PV is the most common disease and represents this kind of potentially life-threatening disease. It is characterized…
By Peggy Clinton, BSN, Eric Hill, Wanda Rogers, RPH As many of you know, Pemphigus is an immune-mediated blistering skin disease involving the IgG autoantibodies which bind to the cell wall of the epidermis. The specific pathway of the blistering…
by Thierry Olivry, DrVet, PhD, DipACVD, DipECVD, Associate Professor of Dermatology, Department of Clinical Sciences, College of Veterinary Medicine, NC State University, Raleigh, North Carolina, and Adjunct Clinical Associate Professor of Dermatology, Department of Dermatology, School of Medicine, University of…
By David A. Sirois, D.M.D., Ph.D.Department of Oral Medicine Pemphigus vulgaris is a chronic autoimmune disease affecting the mucosa and skin and resulting in epithelial acantholysis, bullae formation, and chronic ulceration.1 Skin lesions of pemphigus vulgaris present clinically with typical…
By Sergei A. Grando, MD, PhD, DSci Professor of Dermatology University of California Davis The Need for Alternative Therapies for Pemphigus. In autoimmune pemphigus, systemic glucocorticosteroid treatment is life saving but may cause severe side effects. Pemphigus patients therefore need…
By Sergei A. Grando, M.D., Ph.D., D.Sci. Professor of Dermatology University of California Davis NPF Advisory Board Member The goal of my research is to develop a safer and more rational treatment for pemphigus. I am deeply concerned that we,…
By Edward Tenner M.D.Hoffman Estates, Il. Each type of pemphigus and relate diseases has differing kinds and differing percentages of ocular involvement. Also, the treatments for these diseases have many ocular side effects. Therefore it is very important that an…
By Grant J. Anhalt, M.D. and Hossein Nousari, M.D.Johns Hopkins University, School of Medicine In February 1997, the FDA approved a new drug, mycophenolate mofetil (MFM, also known as Cellcept) with an approved indication for use in immunosuppression of patients…
Grant J. Anhalt, MD Head, Dermatoimmunology Department Johns Hopkins University Baltimore, Maryland Vice President in charge of Scientific Affairs, The International Pemphigus Foundation
Prior to the introduction of an effective therapy with oral corticosteroids in the 1950s, the disease had a dismal natural course with a 50% mortality rate at 2 years and 100%
